Skip to main content

Table 1 Baseline characteristics of patients included (means ± standard deviation, range)

From: Endogenous plasma activated protein C levels and the effect of enoxaparin and drotrecogin alfa (activated) on markers of coagulation activation and fibrinolysis in pulmonary embolism

Variable

DAA 6 μg/kg/h

DAA 12 μg/kg/h

DAA 18 μg/kg/h

DAA 24 μg/kg/h

Placebo

n

6

9

9

8

15

Age (years)

70.8 ± 4.4 (66.0 to 78.0)

65.7 ± 8.9 (46.0 to 74.0)

51.9 ± 16.5 (30.0 to 72.0)

45.6 ± 22.6 (18.0 to 78.0)

60.7 ± 21.9 (22.0 to 84.0)

Sex (Female)

3/6

3/9

5/9

3/8

11/15

Body weight (kg)

76.0 ± 9.7 (60.0 to 85.0)

93.9 ± 13.3 (79.0 to 120.0)

85.2 ± 17.6 (66.0 to 114.0)

86.4 ± 13.8 (62.0 to 104.0)

85.7 ± 18.6 (50.0 to 113.0)

Systolic blood pressure (mmHg)

115.0 ± 15.8 (100.0 to 140.0)

129.1 ± 20.4 (95.0 to 160.0)

129.1 ± 30.7 (95.0 to 188.0)

119.5 ± 16.7 (80.0 to 132.0)

133.7 ± 25.4 (100.0 to 181.0)

Diastolic blood pressure (mmHg)

66.4 ± 10.4 (57.0 to 80.0)

86.4 ± 17.5 (62.0 to 120.0)

82.4 ± 12.7 (70.0 to 104.0)

68.9 ± 12.0 (50.0 to 85.0)

76.6 ± 14.3 (60.0 to 110.0)

Highest heart rate (1/minute)

83.5 ± 14.2 (60.0 to 100.0)

95.2 ± 19.4 (80.0 to 140.0)

94.4 ± 17.3 (75.0 to 127.0)

105.4 ± 21.6 (70.0 to 130.0)

106.6 ± 9.9 (95.0 to 130.0)

Earlier PE

1/6

2/9

0

1/8

0

Earlier DVT

1/6

2/9

1/9

2/8

2/15

Earlier ischemic stroke

1/6

1/9

0

0

3/15

  1. DAA, Drotrecogin alfa (activated); DVT, deep vein thrombosis; PE, pulmonary embolism.